Anteris Technologies Global Corp. — Capital/Financing Update 2023

Nov 2, 2023

==> picture [192 x 28] intentionally omitted <==

ASX ANNOUNCEMENT

3 November 2023

CLEANSING NOTICE UNDER SECTION 708A(5)(e)

On 2 November 2023, Anteris Technologies Ltd (ASX: AVR) ( Anteris or the Company ) issued 1,539,150 new fully paid Ordinary Shares ( New Shares ) to various sophisticated and professional investors at an issue price of $20.00 per new share, raising $30,783,000 before issue costs.

Details of the securities issued

Class of securities: Fully paid ordinary shares ASX code: AVR Date of the issue: 2 November 2023

Total number of securities issued: 1,539,150

Anteris gives notice under section 708A(5)(e) of the Corporations Act 2001 (Cth) (the Corporations Act ) that:

1. the New Shares have been issued without disclosure to investors under Part 6D.2 of the Corporations Act;

2. as at the date of this notice, the Company has complied with:

   • (a) the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and

   • (b) section 674 of the Corporations Act;

3. as at the date of this notice, there is no ‘excluded information’ of the type referred to in sections 708A(7) and 708A(8) of the Corporations Act which is required to be disclosed by Anteris under section 708A(6)(e) of the Corporations Act.

ENDS

==> picture [41 x 41] intentionally omitted <==

REGISTERED OFFICE Toowong Tower, Level 3, Suite 302 9 Sherwood Road Toowong, QLD 4066 Australia

T: +61 1300 550 310 info.au@anteristech.com anteristech.com

BRISBANE | MINNEAPOLIS | GENEVA | MALAGA

==> picture [195 x 28] intentionally omitted <==

About Anteris Technologies Ltd (ASX: AVR)

Anteris Technologies Ltd (ASX: AVR) is a structural heart company committed to designing, developing, and commercialising innovative medical devices. Founded in Australia, with a significant presence in Minneapolis, USA (a MedTech hub), Anteris is science-driven with an experienced team of multidisciplinary professionals delivering transformative solutions to structural heart disease patients.

The Company’s lead product, DurAVR™, is a transcatheter heart valve (THV) for treating aortic stenosis. DurAVR™ THV was designed in partnership with the world’s leading interventional cardiologists and cardiac surgeons. It is the first transcatheter aortic valve replacement (TAVR) to use a single piece of bioengineered tissue. This biomimetic valve is uniquely shaped to mimic the performance of a healthy human aortic valve.

DurAVR[TM] THV is made using ADAPT[® ] tissue, Anteris’ patented anti-calcification tissue technology. ADAPT[®] tissue has been used clinically for over 10 years and distributed for use in over 50,000 patients worldwide.

The ComASUR™ Delivery System was designed to provide controlled deployment and accurate placement of the DurAVR™ THV with balloon-expandable delivery, allowing precise alignment with the heart’s native commissures to achieve optimal valve positioning.

Anteris Technologies is set to revolutionise the structural heart market by delivering clinically superior solutions for significant unmet clinical needs.

Authorisation and Additional information

This announcement was authorised by Mr Stephen Denaro, Company Secretary.

For more information:

Investor Relations (US) Investor Relations Malini Chatterjee, Ph.D. investors@anteristech.com Managing Director Anteris Technologies Ltd Blueprint Life Science Group +61 1300 550 310 | +61 7 3152 3200 +1 917 330 4269

www.anteristech.com Twitter: @AnterisTech Facebook: www.facebook.com/AnterisTech LinkedIn: https://www.linkedin.com/company/anteristech

==> picture [41 x 40] intentionally omitted <==

2